PortfoliosLab logoPortfoliosLab logo
GFRD.L vs. WELL.TO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GFRD.L vs. WELL.TO - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in Galliford Try plc (GFRD.L) and WELL Health Technologies Corp. (WELL.TO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Different Trading Currencies

GFRD.L is traded in GBp, while WELL.TO is traded in CAD. To make them comparable, the WELL.TO values have been converted to GBp using the latest available exchange rates.

Returns By Period

In the year-to-date period, GFRD.L achieves a 2.17% return, which is significantly lower than WELL.TO's 25.40% return. Over the past 10 years, GFRD.L has outperformed WELL.TO with an annualized return of 81.23%, while WELL.TO has yielded a comparatively lower 42.04% annualized return.


GFRD.L

1D
2.54%
1M
-0.19%
YTD
2.17%
6M
1.39%
1Y
33.77%
3Y*
50.95%
5Y*
39.64%
10Y*
81.23%

WELL.TO

1D
4.42%
1M
15.53%
YTD
25.40%
6M
25.86%
1Y
25.23%
3Y*
-4.43%
5Y*
-8.38%
10Y*
42.04%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GFRD.L vs. WELL.TO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
GFRD.L
Galliford Try plc
2.17%39.83%80.36%56.41%-7.25%49.52%244.26%254.41%49.62%126.75%
WELL.TO
WELL Health Technologies Corp.
25.40%-43.39%66.97%31.72%-39.61%-37.97%410.89%250.13%-0.08%196.34%

Correlation

The correlation between GFRD.L and WELL.TO is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.08

Correlation (3Y)
Calculated over the trailing 3-year period

0.07

Correlation (5Y)
Calculated over the trailing 5-year period

0.06

Correlation (10Y)
Calculated over the trailing 10-year period

0.05

Correlation (All Time)
Calculated using the full available price history since Dec 19, 2012

0.05

Fundamentals

Market Cap

GFRD.L:

£542.57M

WELL.TO:

CA$1.29B

EPS

GFRD.L:

£0.72

WELL.TO:

CA$0.12

PE Ratio

GFRD.L:

7.24

WELL.TO:

43.30

PEG Ratio

GFRD.L:

0.08

WELL.TO:

0.00

PS Ratio

GFRD.L:

0.15

WELL.TO:

0.79

PB Ratio

GFRD.L:

4.57

WELL.TO:

1.48

Total Revenue (TTM)

GFRD.L:

£3.76B

WELL.TO:

CA$1.47B

Gross Profit (TTM)

GFRD.L:

£302.70M

WELL.TO:

CA$545.21M

EBITDA (TTM)

GFRD.L:

£128.90M

WELL.TO:

CA$219.35M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GFRD.L vs. WELL.TO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GFRD.L
GFRD.L Risk / Return Rank: 7777
Overall Rank
GFRD.L Sharpe Ratio Rank: 7979
Sharpe Ratio Rank
GFRD.L Sortino Ratio Rank: 7878
Sortino Ratio Rank
GFRD.L Omega Ratio Rank: 7474
Omega Ratio Rank
GFRD.L Calmar Ratio Rank: 7676
Calmar Ratio Rank
GFRD.L Martin Ratio Rank: 7979
Martin Ratio Rank

WELL.TO
WELL.TO Risk / Return Rank: 5858
Overall Rank
WELL.TO Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
WELL.TO Sortino Ratio Rank: 5959
Sortino Ratio Rank
WELL.TO Omega Ratio Rank: 5858
Omega Ratio Rank
WELL.TO Calmar Ratio Rank: 5757
Calmar Ratio Rank
WELL.TO Martin Ratio Rank: 5353
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GFRD.L vs. WELL.TO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Galliford Try plc (GFRD.L) and WELL Health Technologies Corp. (WELL.TO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GFRD.LWELL.TODifference
Sharpe ratioReturn per unit of total volatility

+0.71

Sortino ratioReturn per unit of downside risk

+1.01

Omega ratioGain probability vs. loss probability

1.25

1.15

+0.11

Calmar ratioReturn relative to maximum drawdown

2.23

0.70

+1.54

Martin ratioReturn relative to average drawdown

6.09

1.09

+5.00

GFRD.L vs. WELL.TO - Sharpe Ratio Comparison

The current GFRD.L Sharpe Ratio is 1.35, which is higher than the WELL.TO Sharpe Ratio of 0.64. The chart below compares the historical Sharpe Ratios of GFRD.L and WELL.TO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


GFRD.LWELL.TODifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.35

0.64

+0.71

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

1.30

-0.18

+1.49

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.95

0.62

+0.33

Sharpe Ratio (All Time)

Calculated using the full available price history

0.00

0.17

-0.17

Drawdowns

GFRD.L vs. WELL.TO - Drawdown Comparison

The maximum GFRD.L drawdown since its inception was -86.20%, smaller than the maximum WELL.TO drawdown of -98.56%. Use the drawdown chart below to compare losses from any high point for GFRD.L and WELL.TO.


Loading charts...

Drawdown Indicators


GFRD.LWELL.TODifference

Max Drawdown

Largest peak-to-trough decline

-86.20%

-98.56%

+12.36%

Max Drawdown (1Y)

Largest decline over 1 year

-16.25%

-38.27%

+22.02%

Max Drawdown (3Y)

Largest decline over 3 years

-17.25%

-51.00%

+33.75%

Max Drawdown (5Y)

Largest decline over 5 years

-27.54%

-69.09%

+41.55%

Max Drawdown (10Y)

Largest decline over 10 years

-53.72%

-69.32%

+15.60%

Current Drawdown

Current decline from peak

-7.92%

-48.13%

+40.21%

Average Drawdown

Average peak-to-trough decline

-33.58%

-46.76%

+13.18%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.97%

24.41%

-18.44%

Volatility

GFRD.L vs. WELL.TO - Volatility Comparison

The current volatility for Galliford Try plc (GFRD.L) is 8.11%, while WELL Health Technologies Corp. (WELL.TO) has a volatility of 12.12%. This indicates that GFRD.L experiences smaller price fluctuations and is considered to be less risky than WELL.TO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GFRD.LWELL.TODifference

Volatility (1M)

Calculated over the trailing 1-month period

8.11%

12.12%

-4.01%

Volatility (6M)

Calculated over the trailing 6-month period

19.47%

27.93%

-8.46%

Volatility (1Y)

Calculated over the trailing 1-year period

26.97%

41.70%

-14.73%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

30.43%

45.83%

-15.40%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

85.09%

68.21%

+16.88%

Dividends

GFRD.L vs. WELL.TO - Dividend Comparison

GFRD.L's dividend yield for the trailing twelve months is around 3.81%, while WELL.TO has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
GFRD.L
Galliford Try plc
3.81%3.65%3.99%10.00%5.03%2.61%60.35%64.03%113.00%70.84%60.27%42.31%
WELL.TO
WELL Health Technologies Corp.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

GFRD.L vs. WELL.TO - Financials Comparison

This section allows you to compare key financial metrics between Galliford Try plc and WELL Health Technologies Corp.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B202120222023202420252026
934.90M
368.26M
(GFRD.L) Total Revenue
(WELL.TO) Total Revenue
Please note, different currencies. GFRD.L values in GBp, WELL.TO values in CAD

GFRD.L vs. WELL.TO - Profitability Comparison

The chart below illustrates the profitability comparison between Galliford Try plc and WELL Health Technologies Corp. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

10.0%20.0%30.0%40.0%50.0%202120222023202420252026
8.6%
37.4%
Portfolio components
GFRD.L - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Galliford Try plc reported a gross profit of 80.50M and revenue of 934.90M. Therefore, the gross margin over that period was 8.6%.

WELL.TO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, WELL Health Technologies Corp. reported a gross profit of 137.60M and revenue of 368.26M. Therefore, the gross margin over that period was 37.4%.

GFRD.L - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Galliford Try plc reported an operating income of 21.20M and revenue of 934.90M, resulting in an operating margin of 2.3%.

WELL.TO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, WELL Health Technologies Corp. reported an operating income of 19.76M and revenue of 368.26M, resulting in an operating margin of 5.4%.

GFRD.L - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Galliford Try plc reported a net income of 18.20M and revenue of 934.90M, resulting in a net margin of 2.0%.

WELL.TO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, WELL Health Technologies Corp. reported a net income of -12.38M and revenue of 368.26M, resulting in a net margin of -3.4%.


Frequently Asked Questions


GFRD.L and WELL.TO have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for GFRD.L and WELL.TO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer